BioSpace News Archive

CenSyn, a digital telehealth company advancing portable screening of brain health-related conditions via its platform for integrated brain health screening, is pleased to announce its strategic partnership with HonorHealth, a leading healthcare system serving 1.6 million people in the greater Phoenix area.

Regulatory News: TRANSGENE (Paris:TNG) today announces that Management will participate in several investor events in January and February 2023, as set out below.

Alexis Bio, a private regenerative medicine company, announced that realSKIN™ is the first live cell xenotransplant product to be designated as a Regenerative Medicine Advanced Therapy by the U.S. Food and Drug Administration.

University of Maryland School of Medicine Dean Mark T. Gladwin, MD, has announced plans to launch a new neuroscience institute that will accelerate translational research of the brain by facilitating interaction between basic and clinical scientists and enhancing collaborative research across the UMSOM and University of Maryland, Baltimore campus.

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, and its Board of Directors announced that David A. Cory has resigned as President, Chief Executive Officer and member of the Board of Directors, effective immediately.

MimiVax is pleased to announce the published manuscript of the now completed Phase IIa study of SurVaxM, a cancer vaccine, in newly diagnosed glioblastoma (nGBM) in the Journal of Clinical Oncology, authored by researchers from several prominent US cancer centers.

Sosei Group Corporation (“the Company”; TSE: 4565) announces it has entered a drug discovery collaboration with Eli Lilly and Company (“Lilly”), a global biopharmaceutical company, to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with diabetes and metabolic diseases.